Therefore, FDA-approved drugs targeting PDGFRA, such as regorafenib for colorectal carcinoma and pazopanib for renal carcinoma40,41, may inhibit tumor progression of PPC with high PDGFRA expression. This evidence concerns the gene PDGFRA and colorectal carcinoma.